(Last updated : 2020-03-31 11:19:03)
  谷岡 洋亮
   Department     ,
   Position  
■ Journal
1. 2020/03/24 Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study) 
2. 2020/02/03 Upregulation of microRNA‐31 is associated with poor prognosis in patients with advanced colorectal cancer 
3. 2020/01/21 Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial.  Link
4. 2019/12 A Case of Long-Term Survival after Para-Aortic Lymph Node Recurrence Following the Curative Resection of Gastric Cancer Treated Using Multimodality Therapy Including Salvage Surgery. 
5. 2019/10/11 The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY) 
Display all(12)
■ Presentation
1. 2020/01/23 A phase II study of FOLFOXIRI plus bevacizumab (Bmab) as initial chemotherapy for patients (pts) with untreated metastatic colorectal cancer (mCRC): TRICC1414 (Be TRI).  
2. 2020/01/23 Multicenter phase II study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PII).  
3. 2019/09/29 Primary results of multicenter phase II study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PII)  
4. 2019/09/29 Randomized phase III study of sequential treatment with capecitabine or 5-fluorouracil (FP) plus bevacizumab (BEV) followed by the addition with oxaliplatin (OX) versus initial combination with OX+FP+ BEV in the first-line chemotherapy for metastatic colorectal cancer: The C-cubed study  
5. 2019/07/18 Final analysis of survival outcomes in the KSCC1501A trial of up-front therapy for HER2-negative advanced gastric cancer  
Display all(24)